Cardiovascular mortality in psoriasis and psoriatic arthritis: epidemiology, pathomechanisms, therapeutic implications, and perspectives.
about
Lipid profile changes in patients with chronic inflammatory arthritis treated with biologic agents and tofacitinib in randomized clinical trials: a systematic review and meta-analysisManagement of cardiovascular disease in patients with psoriasis.Association between psoriasis and chronic obstructive pulmonary disease: A systematic review and meta-analysis.Cardiovascular risk in psoriatic arthritis - a cross-sectional study.Association between Psoriasis Vulgaris and Coronary Heart Disease in a Hospital-Based Population in Japan.IL-17 in psoriasis: implications for therapy and cardiovascular co-morbidities.An evolution in switching therapy for psoriasis patients who fail to meet treatment goals.Side effects of TNF-α blockers in patients with psoriatic arthritis: evidences from literature studies.Burden of disease: psoriasis and psoriatic arthritis.Diagnosing and treating psoriatic arthritis: an update.Effect of treating psoriasis on cardiovascular co-morbidities: focus on TNF inhibitors.Barriers to guideline-compliant psoriasis care: analyses and concepts.Dermatological comorbidity in psoriasis: results from a large-scale cohort of employees.Serum YKL-40 as a potential biomarker of inflammation in psoriasis.Adiponectin regulates psoriasiform skin inflammation by suppressing IL-17 production from γδ-T cells.Psoriasis and Cardiovascular Risk-Do Promising New Biomarkers Have Clinical Impact?Methotrexate and anti-tumor necrosis factor treatment improves endothelial function in patients with inflammatory arthritisMetabolic syndrome and its relationship with the achievement of minimal disease activity state in psoriatic arthritis patients: an observational study.The use of the tyrosine kinase inhibitor Nilotinib in Spondyloarthritis: does targeting inflammatory pathways with a treatment lead to vascular toxicity?The Use of Primary Prevention Statin Therapy in Those Predisposed to Atherosclerosis.Impact of 24-month treatment with etanercept, adalimumab, or methotrexate on metabolic syndrome components in a cohort of 210 psoriatic arthritis patients.Endothelial function is impaired in the cutaneous microcirculation of adults with psoriasis through reductions in nitric oxide-dependent vasodilation.Factors associated with accelerated subclinical atherosclerosis in patients with spondyloarthritis without overt cardiovascular disease.Serum complement C3 correlates with insulin resistance in never treated psoriatic arthritis patients.Unmet Needs in the Field of Psoriasis: Pathogenesis and Treatment.
P2860
Q26859516-B0BAB990-3C74-41B0-B340-9D4FA8E88429Q30250278-52ED234B-ABEB-40DA-B808-FC821D18F8E5Q30252078-8DD0183E-5151-4C78-9049-03B19536BDCAQ34717077-CE3882B0-5911-439E-90C4-37BACBDFF0E2Q35934076-2B09AEB5-2C1C-4D42-8CE5-8F083BC153CAQ36807407-B504854E-9545-44A8-90D2-B04709E80895Q37295966-E472BFBF-55C6-49F1-9CD1-6D1B6613CC5CQ38099248-5EC3F583-DF3B-4D6D-82D6-0689F6C9DB3EQ38114850-BD2C5230-0C2E-40C7-AB23-504CAD2B1FD4Q38165235-BAA5F3EF-A386-4FEA-9CFE-D5300F9B1609Q38166661-DDBAF728-D655-45F6-B8A6-12ABC2ACB205Q38625686-93CB83E8-0E8D-49F0-A8EC-E1A0C68D6BE6Q38839027-9D844156-4FD5-4749-90DB-86BA8CFD361FQ40215575-73BA7D6C-897A-4CBC-83BB-2EBB4E0FE0AAQ40738483-C2DEC173-E8CA-4403-BF99-00C75782A6B6Q41693144-308E0A04-F922-4942-B79F-6C363D819B9FQ42682318-A45A5AE5-2BDC-4717-86E3-528518121004Q43727420-AFBE8A39-9A50-478B-963B-DF0C972A3582Q47159332-EB108AC9-9388-4935-8D85-99DB9FF78C04Q47610317-AFD4B5E3-51D5-46C3-8497-349E0E0BF8AEQ47743748-400F73B3-1342-42FD-B3E0-E2144311DBD0Q47750772-1EE97FB2-A4D8-4354-994C-878BBF13ADFCQ48007635-1FDCE3ED-C9BF-44C8-BEA3-C7C89001E258Q50776527-58B2476B-9502-4FB8-A4F8-60C0DEA0C357Q53123754-68DF8CC4-9398-49E4-A6EF-5ACD987D75A0
P2860
Cardiovascular mortality in psoriasis and psoriatic arthritis: epidemiology, pathomechanisms, therapeutic implications, and perspectives.
description
2012 nî lūn-bûn
@nan
2012 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Cardiovascular mortality in ps ...... mplications, and perspectives.
@ast
Cardiovascular mortality in ps ...... mplications, and perspectives.
@en
Cardiovascular mortality in ps ...... mplications, and perspectives.
@nl
type
label
Cardiovascular mortality in ps ...... mplications, and perspectives.
@ast
Cardiovascular mortality in ps ...... mplications, and perspectives.
@en
Cardiovascular mortality in ps ...... mplications, and perspectives.
@nl
prefLabel
Cardiovascular mortality in ps ...... mplications, and perspectives.
@ast
Cardiovascular mortality in ps ...... mplications, and perspectives.
@en
Cardiovascular mortality in ps ...... mplications, and perspectives.
@nl
P2860
P1476
Cardiovascular mortality in ps ...... mplications, and perspectives.
@en
P2093
Sandra Boehncke
Wolf-Henning Boehncke
P2860
P2888
P304
P356
10.1007/S11926-012-0260-8
P577
2012-08-01T00:00:00Z
P6179
1042530297